ATUM

ATUM (formerly DNA2.0) is a biotechnology company that provides advanced tools for the design and synthesis of optimized DNA, alongside comprehensive solutions for protein production and GMP cell line development. Its platform leverages machine learning and computational biology to engineer and manufacture genes and proteins, significantly streamlining the discovery and development processes for various life science applications. ATUM’s integrated approach allows clients to accelerate their research and bring new biological products to market more efficiently.

The company was founded in 2003 by a team of visionary scientists including Sridhar Govindarajan, Claes Gustafsson, Jeremy Minshull, and Jon Ness. Their collective insight centered on the transformative potential of applying computational design principles and automated synthesis to genetic engineering, moving beyond traditional, slower methods. This pioneering approach aimed to optimize biological systems and processes from the ground up, establishing ATUM as a leader in synthetic biology.

ATUM primarily serves researchers and developers across the biopharmaceutical, industrial biotechnology, and academic sectors who require precise genetic constructs and efficient protein manufacturing. The company’s overarching vision is to be the essential partner for life science innovation, enabling its customers to push the boundaries of what is possible in biotechnology through sophisticated design, synthesis, and production technologies.